Prof Brooks

High-Tech Imaging to Enhance Prostate Cancer Diagnosis

Doug Brooks from the University of South Australia’s School of Pharmacy and Medical Sciences is conducting lifesaving prostate cancer research to improve the way men are managed when diagnosed with prostate cancer.

Australian Prostate Cancer (APC) in partnership with The Hospital Research Foundation (THRF) is proud to have made a significant contribution, with the University of South Australia (UniSA), towards the purchase of a 3D Histech Pannoramic confocal scanner that will assist Prof Brooks and his team in detecting prostate cancer through a high-tech system.

The 3D scanner has the potential to not only detect if a man has prostate cancer but also determine if it’s in the early stages or advanced, something current diagnostic tools cannot detect.

Currently prostate cancer is detected through a Prostate-Specific Antigen (PSA) test, however doctors are unable to confirm through PSA levels how aggressive the cancer is, sometimes resulting in radical treatments which may not be necessary. This understandably creates an enormous amount of stress and uncertainty for the patient and their loved ones which they shouldn’t have to experience.

“The 3D scanner will help us to change the way men are diagnosed with prostate cancer and eliminate the chances of misdiagnosis through PSA levels,” Prof Brooks said.

“This scanner will accurately detect the cancer to enable doctors to choose the correct treatment method for individual patients.”

Prof Brooks’ lifesaving research would not be possible without the purchase of this 3D scanner. The state-of-the-art imaging machine takes approximately 40,000 images per tissue sample, which is then pieced together to produce a high quality image allowing the prostate cancer to be easily detected.

With your donation today, you will ensure the research using this cutting-edge technology can continue, bringing us closer to our goal.


“This groundbreaking technology enables us to be one step closer to better diagnosis and treatment methods for men suffering with prostate cancer. This has never been done before,” Prof Brooks said.

Collaborating with Trinity College Dublin, Prof Brooks has around 1,000 tissue samples from both Ireland and Adelaide being scanned through this machine. He plans to complete a pre-clinical study in the next six months to validate his claim that this machine can detect prostate cancer.

“Thanks to the generosity of APC and partner THRF, this imaging machine can now be used to facilitate a pre-clinical study.

“Although these new imaging technologies have specific applications for prostate cancer, the technology will apply to other cancers, giving this project wider and exciting potential in cancer imaging.”

With your continued support, Prof Brooks and his team will revolutionise the way clinicians and doctors diagnose and treat prostate cancer. It will save lives.

Would you like to support vital research like Prof Brooks’ today?

2 thoughts on “High-Tech Imaging to Enhance Prostate Cancer Diagnosis

  1. Phil Heaton

    That is wonderful work but tell me, if the test requires tissue samples, I am assuming that cannot come from the blood work rather an invasive biospy?

    1. Australian Prostate Cancer Post author

      Hi Phil, who better to respond to you but the wonderful Professor Doug Brooks – this is his reply to your query:

      We are developing a non-invasive blood test to augment or replace the PSA test. The problem currently is that many people without cancer are currently undergoing a biopsy. We aim to correct that major problem.

      The biomarkers we are developing can also be used on tissue biopsies to help confirm the diagnosis and to define the tumour size and architecture. This will also be used to help predict how aggressive the cancer is. This part of the new biomarker technology is what THRF are helping us to achieve. This information will help decide which therapy is needed or if the patient can just go on a monitoring program.

      Finally we have a set of gene biomarkers that can also be evaluated on patient tissue to accurately predict prognosis. We are wanting to do a pre-clinical study to prove this technology works.

      We are trying to develop each of these three technologies so that we can have a solution on how to accurately detect, monitor and treat prostate cancer patients.

      THRF are directly supporting this research program through equipment support and this will help us with our pre-clinical studies. We are currently looking at several biomarkers that enable us to see the prostate tumours in great detail.

      All the best


Leave a Reply

Your email address will not be published. Required fields are marked *